Every material Form 8-K Arcus Biosciences filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Arcus Biosciences reported third-quarter 2026 results on November 4, 2026. Quarterly revenue fell to $9 million from $26 million, while the net loss narrowed to $128 million from $135 million, and the company said cash runway extends into 2029 after an October equity financing.
Q3 2026 net loss was $128 million, or $1.00 per share, versus $135 million, or $1.27 per share, in Q3 2025.
Q3 2026 revenue was $9 million versus $26 million a year earlier; the company expects full-year 2026 GAAP revenue of $70 million to $75 million.
Cash, cash equivalents and marketable securities were $694 million at September 30, 2026, plus $288 million gross proceeds from an October equity financing.
Enrollment in the PEAK-1 Phase 3 study is expected to complete in the next two to three months; PEAK-20 is expected to begin in the fourth quarter of 2026.
Arcus Biosciences sold 16,428,572 shares of common stock at a public offering price of $17.50 per share, including the full exercise of the underwriters' option, and the offering closed on October 23, 2026. The company received net proceeds of approximately $269.7 million after underwriting discounts, commissions and estimated offering expenses. Shareholders face a larger share count, and the filing does not describe how the proceeds will be used.
Public offering price of $17.50 per share; underwriters agreed to buy the shares from the company at $16.45 per share.
Total of 16,428,572 shares issued, including 2,142,857 shares from the underwriters' option exercised in full.
Offering closed October 23, 2026, with net proceeds of approximately $269.7 million.
Underwriters were Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC, under Form S-3 Registration No. 333-293750.
Arcus Biosciences disclosed a preliminary estimate of about $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. The figure is unaudited, subject to financial closing procedures, and Ernst & Young has not reviewed it, so it may change. The filing contains no revenue, profit or guidance figures, so it gives shareholders a liquidity snapshot rather than full results.
Preliminary cash, cash equivalents and marketable securities: approximately $694.0 million as of September 30, 2026
Figure is unaudited and subject to completion of financial closing procedures and management review
Ernst & Young LLP has not audited or reviewed the preliminary data
Filing does not include revenue, net income, EPS or guidance
Arcus Biosciences presented new data from its ARC-20 platform study of casdatifan, alone or in combination, for clear cell renal cell carcinoma, using a data cutoff of September 4, 2026. The filing reports response, progression and survival figures across first-line, second-line and late-line cohorts, with no unexpected safety signals cited for each regimen.
Second-line casdatifan plus cabozantinib (n=43): median PFS 14.5 months, 18-month landmark overall survival 77%, cORR 44%
First-line casdatifan plus zimberelimab (n=30): cORR 50%, landmark PFS 69% at 12 months, primary progression 6.7%
Late-line casdatifan monotherapy (n=121): median overall survival 35 months, median PFS 13 months, cORR 36%
Arcus Biosciences reported second-quarter 2026 revenue of $41 million, down from $160 million a year earlier, and a net loss of $91 million, compared with break-even results in the same period of 2025. The company expects GAAP revenue of $65 million to $75 million for full-year 2026 and ended the quarter with $775 million in cash, cash equivalents and marketable securities.
Q2 2026 revenue was $41 million versus $160 million in Q2 2025, mainly because 2025 included a $143 million catch-up from license and development services revenue tied to etrumadenant.
Q2 2026 net loss was $91 million, or $0.72 per share; six-month net loss was $219 million, or $1.74 per share.
Full-year 2026 GAAP revenue is expected at $65 million to $75 million, and year-end 2026 cash is expected to be about $600 million.
Gilead relinquished its three Board of Directors seats effective August 5, 2026, following the wind-down of Phase 3 anti-TIGIT studies.
Arcus Biosciences reported first-quarter 2026 results, with revenue of $17 million, down from $28 million a year earlier, and a net loss of $128 million, up from $112 million. Net loss per share was $1.02, compared with $1.14, on a higher share count of 125.4 million versus 98.4 million. Cash, cash equivalents and marketable securities fell to $876 million, and the company expects to end 2026 with about $600 million.
Revenue was $17 million for Q1 2026, versus $28 million in Q1 2025, mainly from lower development services revenue from the Gilead collaboration.
Net loss was $128 million, versus $112 million; basic and diluted loss per share was $1.02, versus $1.14.
Cash, cash equivalents and marketable securities were $876 million at March 31, 2026, versus $1.0 billion at December 31, 2025.
Arcus expects full-year 2026 GAAP revenue of $50 million to $65 million and cash runway until at least the second half of 2028.
Arcus Biosciences said Chief Operating Officer Jennifer Jarrett decided to resign, effective March 30, 2026, and that the resignation is not due to any disagreement with the company on operations, policies or practices. Under a separation agreement, she will provide periodic advisory services through June 30, 2026, and the company extended her post-termination option exercise period to twelve months.
Jennifer Jarrett resigns as Chief Operating Officer, effective March 30, 2026; notice given March 17, 2026
Resignation is stated to be unrelated to any disagreement with the company
Jarrett will provide advisory services through June 30, 2026; vested options exercisable for twelve months after termination
Full separation agreement to be filed with the next Form 10-Q
Arcus Biosciences reported fourth-quarter and full-year 2025 results on February 25, 2026. Revenue declined and the net loss widened for both periods, and the company gave 2026 GAAP revenue guidance of $45 million to $55 million. Arcus and Gilead are winding down the Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies, and the company expects R&D expenses to decrease meaningfully in 2026.
Full-year 2025 revenue was $247 million, down from $258 million in 2024; net loss was $353 million, or $3.29 per share, versus $283 million, or $3.14 per share in 2024
Fourth-quarter 2025 revenue was $33 million, down from $36 million; net loss was $106 million, compared with $94 million a year earlier
Company expects GAAP revenue of $45 million to $55 million for full-year 2026
Cash, cash equivalents and marketable securities were $1.0 billion at December 31, 2025, versus $992 million a year earlier, with funding expected until at least the second half of 2028
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Arcus Biosciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →